Latest News for: biogen

Edit

Biogen at AAIC 2026 Presentation (Biogen Inc)

Public Technologies 14 Jul 2026
). The text version of this document is not available ... Disclaimer. Biogen Inc.
Edit

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease (Biogen Inc)

Public Technologies 14 Jul 2026
). The text version of this document is not available ... Disclaimer. Biogen Inc.
Edit

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The Economic Times 14 Jul 2026
The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug ...
Edit

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau ...

Nasdaq Globe Newswire 14 Jul 2026
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc ... 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.1 .
Edit

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and ...

Business Wire 14 Jul 2026
IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating ...
Edit

Alzheimers New Experimental Drugs

Decatur Daily 14 Jul 2026
These brain scan images provided by Biogen show how high levels of Alzheimer's-related tau protein, in red, dropped in a recipient of the company's experimental drug diranersen. [BIOGEN VIA AP] ... .
Edit

Here are Monday's biggest analyst calls: Nvidia, SpaceX, Tesla, Apple, Netflix, Deckers, Biogen, Nio & more

CNBC 13 Jul 2026
Here are Monday's biggest calls on Wall Street ... .
Edit

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease (Biogen Inc)

Public Technologies 13 Jul 2026
). The text version of this document is not available ... Disclaimer. Biogen Inc.
Edit

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 (Biogen Inc)

Public Technologies 12 Jul 2026
). The text version of this document is not available ... Disclaimer. Biogen Inc.
Edit

Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) July 14, 2026 (Biogen Inc)

Public Technologies 07 Jul 2026
). The text version of this document is not available ... Disclaimer. Biogen Inc.
Edit

Business/Financial Results (Form 8-K) (Biogen Inc)

Public Technologies 01 Jul 2026
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis ... Biogen Inc.
Edit

Preliminary Q2 2026 Acquired IPRD & Licensing Income (Biogen Inc)

Public Technologies 01 Jul 2026
Biogen Inc ... Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis.
Edit

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA ...

Nasdaq Globe Newswire 29 Jun 2026
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq ... .
Edit

Why Biogen (BIIB) Stock Is Up Today

The Call 26 Jun 2026
Shares of biotech company Biogen (NASDAQ ... The acquisition of RayThera is set to bolster Biogen's immunology pipeline ... Is now the time to buy Biogen? Access our full analysis report here, it’s free.What Is The Market Telling Us.
Edit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

PR Newswire 25 Jun 2026
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ ... The investigation concerns whether Biogen ...

Article Search

tools
×
×
×
×